Navigation Links
Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients
Date:2/28/2008

SAN DIEGO, Feb. 28 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) today announced that patient dosing has commenced in a Phase I study of ANA773, the company's oral TLR7 agonist prodrug, in patients with advanced solid tumors. This first-in-human trial is a safety and tolerability study designed to identify pharmacologically active doses and preliminary antitumor activity as well as to select the dose and schedule for Phase II trials.

The Phase I trial is a multiple, ascending dose study conducted at several sites in the United States. In addition to safety and tolerability, patients will be monitored for pharmacodynamic responses indicative of immunological stimulation. Initially, patients will be dosed every other day. The company also expects to investigate additional schedules during this first clinical trial and anticipates that up to 60 patients will be enrolled in the study.

"The extensive preclinical investigation Anadys has conducted with ANA773 over the last 18 months has taught us much about the pharmacology of orally administered TLR7 agonists, including the importance of schedule in sculpting the profile of immune activation," said James Freddo, M.D., Anadys' Chief Medical Officer. "We believe ANA773 holds promise for the treatment of a range of malignancies and may have utility when combined with targeted agents, therapeutic antibodies and/or chemotherapy. We are excited about having initiated this first clinical study."

Steve Worland, Ph.D., Anadys' President and Chief Executive Officer, said, "This is an important milestone for Anadys. The initiation of this trial marks the resumption of our clinical investigation of oral TLR7 agonists and moves us closer toward our objective of
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference
2. Anadys Pharmaceuticals to Report Fourth Quarter and Year-End 2007 Financial Results
3. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
4. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
5. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
6. Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
7. Anadys Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw Healthcare Conference
8. Anadys Pharmaceuticals to Report Third Quarter 2007 Financial Results
9. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
10. Memory Pharmaceuticals to Announce Fourth Quarter and Full Year 2007 Results on Thursday, March 6, 2008
11. Michael J. Simms Joins Alexza Pharmaceuticals as Senior Vice President, Operations and Manufacturing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... , Aug. 21, 2014 ... Immune Pharmaceuticals Inc., a biotechnology company, on its ... Immune previously traded on OTCQX®, the best marketplace ... OTC Markets Group. Logo - http://photos.prnewswire.com/prnh/20110118/MM31963LOGO ... on the successful execution of its growth strategy ...
(Date:8/21/2014)... 2014 Gallus BioPharmaceuticals , ... and manufacturing organization (CMO) announced today that it ... oncology company focused on the development of innovative ... the anti-prostate specific membrane antigen (PSMA) monoclonal antibody ... Under the agreement the antibody will be produced ...
(Date:8/20/2014)... it that American Indians largely were wiped out by ... tuberculosis brought to the New World by European explorers., ... people lived in the Americas shortly before Europeans arrived, ... European diseases., But new research led by anthropological geneticists ... of the University of Tubingen in Germany indicates the ...
(Date:8/20/2014)... BOSTON , Aug. 20, 2014  PAREXEL International ... it will be presenting at the Baird Healthcare Conference ... President and Chief Financial Officer, will be making a ... p.m. EDT on Wednesday, Sept. 3, 2014. ... through the "Investors" section of PAREXEL,s website at ...
Breaking Biology Technology:OTC Markets Group Congratulates Immune Pharmaceuticals on NASDAQ Listing 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 3Unusual discovery leads to fascinating tuberculosis theory 2Unusual discovery leads to fascinating tuberculosis theory 3PAREXEL International To Present At Baird Healthcare Conference 2
... the past month, I've seen a half dozen great ... technology market. The products vary widely from unique hardware ... mobile services and beyond. Each concept is carefully conceived ... and each product meets a real and unfulfilled need ...
... At a meeting Monday highlighting university-business partnerships in Wisconsin, ... company based in Hartland, Wis., demonstrated its latest tool ... secretary of commerce for the U.S. Patent and ... R-Wis. The nations highest ranking patent official also met ...
... about asking whether technology drives business or business drives technology. ... Silence all the rattling about how superior this technology is ... certain questions that if you have to ask, you probably ... more satisfying line of inquiry is how much of your ...
Cached Biology Technology:Where have all the angels gone? 2Where have all the angels gone? 3Where have all the angels gone? 4Sensenbrenner and USPTO Director highlight benefits of technology transfer 2Sensenbrenner and USPTO Director highlight benefits of technology transfer 3Technology as the engine of business innovation 2Technology as the engine of business innovation 3
(Date:8/21/2014)... Carolina State University have developed a novel and versatile ... applications for creating new materials as well as for ... technique allows us to model much larger and more ... quickly," says Nan Li, lead author of a paper ... State,s Department of Materials Science and Engineering. "This is ...
(Date:8/20/2014)... Institute (HCI) at the University of Utah have identified ... BCR-ABL, the unregulated enzyme driving the blood cancer chronic ... nearly 6,000 new cases of CML will be diagnosed ... kinase inhibitors (TKIs), target BCR-ABL and are effective at ... control it in a way that allows patients to ...
(Date:8/20/2014)... visible in in this image of the Para and ... were most likely intentionally set in order to deforest ... or stand of trees where the land is thereafter ... conversion of forestland to farms, ranches, or urban use. ... of the Amazon Rainforest in the middle of the ...
Breaking Biology News(10 mins):Researchers develop models to study polyelectrolytes, including DNA and RNA 2Blueprint for next generation of chronic myeloid leukemia treatment 2
... serious and growing environmental problem, especially on the Indian ... years ago, used genetic techniques to create "arsenic-eating" plants ... was a problem, however. The arsenic sequestered from soil ... it difficult to harvest for safe disposal. Now, the ...
... from the University of Montana, University of California - ... have shown that a top predator strongly affected plants ... web by eating organisms that transport nutrients between ecosystems. ... by thwarting nutrient subsidies," is published in the February ...
... Antiretroviral therapy (ART) for infants born with HIV infection ... five months of life, according to a study published ... Infectious Diseases, now available online. , Uncertainty over when ... from their mothers revolves around balancing the benefits of ...
Cached Biology News:Researchers discover way to transport environmental arsenic to plant leaves in new clean-up strategy 2Not just the birds 2Not just the birds 3New study shows benefit of early therapy in HIV-infected infants 2
... cells form from a hematopoietic stem cells ... to the bone surface and lowering the ... around 4.5. The bone mineral is then ... and function is controlled primarily by Macrophage ...
... Proliferator-Activated Receptor-gamma (PPAR) is a member ... ligand-activated transcription factors that heterodimerize with ... involved in the regulation of glucose ... (TZD) class of anti-diabetic agents called ...
... acid hybridization Preparation Reconstitution: one ... 50 mg ficoll and 50 ... ml of water yields a ... biology Density: 1.00 g/mL (20 ...
... The ProteinChip Antibody ... assay development and optimization ... evaluate antibody-antigen interactions. This ... and differentiation of multiple ...
Biology Products: